Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

Extended off-treatment follow-up of CLL14 reporting MRD dynamics after venetoclax-obinutuzumab, including durability of undetectable MRD and its association with outcomes. Level 2.

J Clin OncolPubMed 34709929